Kbc Group Nv Eiger Bio Pharmaceuticals, Inc. Transaction History

Kbc Group Nv

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$5.12 - $8.19 $79,872 - $127,763	-15,600 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$7.82 - $9.23 $57,086 - $67,379	7,300 Added 87.95%	15,600 $133,000
Q2 2020 Aug 10, 2020	BUY	$5.4 - $13.37 $8,640 - $21,392	1,600 Added 23.88%	8,300 $80,000
Q4 2019 Feb 11, 2020	SELL	$9.77 - $15.66 $34,878 - $55,906	-3,570 Reduced 34.76%	6,700 $100,000
Q3 2019 Nov 07, 2019	BUY	$9.59 - $12.0 $98,489 - $123,240	10,270 New	10,270 $105,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $556M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.